parkinson's and glp 1 Use of Glucagon-Like Peptide-1 Beyond insulin: The Intriguing role

The science of transdermal patches: what works and what doesn't Why "GLP-1 patches" is misleading Inside the patch: an ingredient-by-ingredient look What real customers actually say Cost: are Kind Patches good value

Report suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)

Currently, there is no evidence to support using GLP-1 agonists as a primary replacement for standard immunosuppressive therapy

GLP-1s are no longer just weight-loss drugs

Your provider must document BMI, relevant comorbidities (diabetes, hypertension, cardiovascular markers), and why GLP-1 therapy aligns with clinical guidelines

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials